CONNECT WITH US
Thursday 3 July 2025
SAC Group, member of WPG Holdings, partners with Axelera AI to expand into edge AI market and map out new blueprint for smart applications
As generative AI and edge computing technologies continue to evolve, Edge AI has become a key driving force for industries pursuing smart transformation. Recognizing this opportunity, Silicon Application Corp. (SAC) Group, a subsidiary of WPG Holdings and a global leader in semiconductor component distribution, announced today that it has obtained exclusive distribution rights for Axelera AI - an emerging European Edge AI chip company - in the Asia-Pacific region. The two parties will collaborate to combine SAC's strengths in supply chain integration with Axelera AI's technological innovation, aiming to help equipment manufacturers accelerate the development of Edge AI devices, enable independent software vendors (ISVs) to innovate more rapidly, and enhance the capabilities of system integrators (SIs) in deploying their smart applications."To promote the widespread adoption of AI, we launched the global partner program - the Axelera Partner Accelerator Network Program. We are pleased to have WPG Holdings' SAC Group as our core strategic partner in the Asia-Pacific region, working together to accelerate the implementation and application of Edge AI solutions," said John Wilkins, Global Channel Sales Director at Axelera AI. Wilkins pointed out that SAC brings deep technical resources, long-standing customer relationships, and a strong commitment to innovation - qualities that make them the ideal partner to bring our transformative AI technologies to broader markets. Through our partnership with SAC, we believe that equipment manufacturers, SIs, and ISVs will be able to adopt Axelera AI's highly flexible, high-performance, and scalable Edge AI solutions more quickly. This will shorten development cycles from proof of concept to mass production, and accelerate the deployment of smart applications from edge to cloud across various fields such as security surveillance, drones, retail, healthcare, and industrial automation.""The SAC Group's vision of promoting smart applications through Edge AI aligns perfectly with Axelera AI's core mission of driving the widespread adoption of AI technologies," said Lawrence Chang, Vice President of Tactical Development BU at WPG Holdings' SAC Group. He noted that many of the product lines currently distributed by SAC already support Edge AI applications, spanning diverse scenarios such as smart manufacturing, smart buildings, and in-vehicle systems. This collaboration will further enhance and complete SAC's Edge AI product portfolio. Looking ahead, SAC will continue to strengthen its technical support capabilities, offering customers end-to-end services - from early-stage evaluation and product selection recommendations to system integration testing. This will help clients adopt Edge AI technologies and solutions more efficiently, as they move together toward a fully intelligent AI-driven future."In the first half of 2025, WPG Holdings achieved the highest global revenue among semiconductor distributors and has consistently led the industry in technological investment related to computing chips," said Eddie Chou, Senior Project Director in the CEO Office at WPG Holdings. Since the rapid rise of AI in 2023, WPG Holdings has launched an AI acceleration initiative focused on three core areas. On the product front, the company has expanded its AI product portfolio to meet growing customer demand and has been recognized by over 30 suppliers of AI-related chips - including those specializing in compute, power management, and other critical components supporting AI applications. It is now fully capable of providing a complete range of hardware and resources required for AI servers and data centres. In terms of services, WPG Holdings has trained its sales teams to gain a deep understanding of AI project requirements. In addition to basic component support, it now offers advanced, integrated sales services for system-level servers and AI computing power management. From an investment perspective, WPG Holdings has participated in strategic investments in advanced-process IC design, helping more strategic partners build a thriving and collaborative AI ecosystem. Aspiring to become a key player in the AI industry chain, WPG Holdings' reliable partnership with Axelera AI serves as a concrete step toward realizing a mutually beneficial and prosperous future for the whole industry.
Wednesday 2 July 2025
AI meets RNA: InFocus's advanced RNA-targeted small molecule therapeutic platform accelerates drug development
While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development continue to face a multitude of obstacles, such as complex methodologies, high R&D costs, limited target options, and poor translational efficacy. This is particularly relevant for gene or RNA-level abnormalities, which are not effectively addressed by protein-targeting therapeutics, limiting their clinical impact.The rapid advancement in RNA biology has triggered a surge of interest and investment from pharmaceutical companies and the capital markets, accelerating the explosive growth of the RNA therapeutic sector. InFocus Therapeutics is leading this momentum, combining AI with RNA science to create the world's first and currently only "RNA-targeted small molecule drug generation platform." In just four months, InFocus successfully generated two series of drug candidates for spinal muscular atrophy (SMA) and advanced them to the animal efficacy and toxicity testing phase, demonstrating exceptional research and development efficiency.According to Emily Fang, CEO and founder of InFocus Therapeutics, the traditional drug development method is labor-intensive, time-consuming, and marked by a low success rate. In recent years, major pharmaceutical companies have poured significant resources into RNA-based therapies. Yet, a lack of innovative R&D strategies continues to limit their potential. On the other hand, most AI startups struggle to deliver true breakthroughs in this domain, largely due to a lack of real-world experience in early drug discovery and the complex process of transforming molecules into clinically viable, patentable drug candidates.InFocus rapidly gained traction by leveraging the team's deep expertise in AI and RNA technology, the discovery of novel chemical entities that differentiate from competitors and existing marketed drugs. In just four months, they identified two sets of promising therapeutic candidates, an achievement unmatched in the industry and now a key competitive advantage.40x Faster R&D Efficiency: Unlocking the Power of RNA-Targeted MedicinesFounded in 2023, InFocus Therapeutics specializes in the development of small-molecule chemical drugs that directly target RNA, an area poised to reshape modern therapeutics. The company brings together a multidisciplinary team of experts spanning molecular biology, AI algorithms, finance, and RNA drug discovery. Designed to tackle high-impact, hard-to-treat conditions such as neurodegenerative diseases and metastatic cancers, InFocus has built a proprietary RNA-targeted small molecule drug generation platform that integrates advanced AI algorithms and specialized databases to automate the lead discovery process, from molecular design and generative chemistry to structure prediction and experimental validation. The result: a breakthrough platform that delivers up to 40 times greater R&D efficiency, rapidly uncovering best-in-class drug candidates far beyond the reach of conventional methods.Using spinal muscular atrophy (SMA) as a case study, InFocus's platform efficiently identified two promising compounds, IFT-0000002 and IFT-0000003, within a remarkably short timeframe. Both compounds demonstrated strong biological activity, good oral absorption, and toxicological profiles, establishing a solid foundation for further development. CEO Emily Fang highlighted that the InFocus platform achieves a 40% success rate in RNA-targeted drug development, far surpassing the typical ~1% success rate of traditional small-molecule drug development. This high efficiency represents a core competitive advantage for the company.Raising Capital to Accelerate Pipeline ExpansionInFocus is currently raising a US$1 million angel round to support critical next steps. The funds will be deployed to complete the preclinical development and animal studies for the SMA program, and to launch R&D on two new RNA-targeted cancer programs for drug-resistant prostate cancer and colorectal cancer. These efforts will significantly expand the depth and breadth of the platform's therapeutic reach.Commitment to Establish and Grow Taiwan as a Clinical Hub for Strategic CollaborationsTaiwan boasts a comprehensive health insurance system, a world-class medical system, a highly digitized medical record system, and a plethora of clinical research capabilities. It has long been the favored site for clinical trials for international pharmaceutical corporations. InFocus Therapeutics views Taiwan as a key launchpad for clinical collaboration and regional expansion, and plans to set up a subsidiary in 2025. It will engage with the company's proposed clinical trial application framework for 2026 and formally commence the product's admission into the clinical validation phase, while also accelerating the recruitment of local talent and partnering with clinical collaborators.Emily shared that when seeking collaboration opportunities in Taiwan, she fortuitously connected with Taiwan Tech Arena (TTA) and joined its startup incubation program. InFocus gained valuable support and mentoring resources from the Mosaic accelerator, laying the groundwork for future investment and global market expansion. "Soon after our partnership with TTA, we engaged in the 2024 Founder Pitch event, which markedly improved our visibility and fostered connections within the investment community."Alongside its R&D milestones, InFocus is actively expanding its international investor network via TTA, aiming to accelerate the completion of its angel round fundraising and reinforce InFocus's leadership position in RNA-targeted small molecule therapeutics. With its AI-powered platform, high development success rate, and global footprint, InFocus is charting the path toward long-term growth in one of biotech's most promising frontiers.InFocus-BFMTV: InFocus founder Emily Fang was interviewed by renowned economist Nicolas Doze on BFM Business, France's number one financial news channel, and announced that it had received the Sanofi-sponsored 2024 Oncology "Golden Ticket" prize.InFocus Lab in a Loop: InFocus's proprietary artificial intelligence RNA drug discovery technology can generate high clinical potential therapeutic candidates targeting pathogenic RNA within a few months.
Tuesday 1 July 2025
Using AI to address chronic disease care challenges: AIM opens door to precision care for all
In an aging society, the care of chronic diseases has become a major social burden and has imposed significant impacts on the healthcare system. Elderly patients often face complicated medical procedures, unclear disease progression, and overcrowded settings in large hospitals. In 2010, Eric Lee returned to Taiwan from abroad to care for his mother, who had long suffered from chronic diseases related to bone and heart health, and went through firsthand the complexities of the healthcare system-ranging from resource bottlenecks to delayed diagnoses. Motivated by his personal journey, Lee co-founded AIM with physician Dr. Michael Yen in 2018. The company officially launched its product development activities in late 2020, focusing on solving pain points in chronic disease care for the elderly population through state-of-the-art AI diagnostic imaging technology.With Taiwan on the brink of becoming a super-aged society, diseases such as osteoporosis and degenerative arthritis are increasingly prevalent. However, early symptoms are often unnoticed or ignored, causing many patients to miss optimal treatment windows. Traditional diagnosis modalities like DXA bone densitometry or costly CT/MRI scans are time-consuming to schedule and not widely available, making large-scale community screening difficult. Furthermore, cardiac function assessment relies heavily on cardiologists operating advanced ultrasound systems, creating a bottleneck in primary care and public health services.Making Precision Care Accessible: The AI Revolution in X-ray and UltrasoundAccording to Lee, AIM's core technology leverages patented proprietary deep learning algorithms to analyze medical images from standard X-ray and ultrasound equipment. Its flagship solution, DeepXray, delivers automated bone density and joint degeneration analysis in under 30 seconds, generating clinically relevant reports. Validated by leading medical institutions including Taichung Veterans General Hospital, Taipei Medical University Shuang-Ho Hospital and Far Eastern Memorial Hospital, DeepXray achieves over 0.9 correlation with gold-standard DXA scans and maintains a world-class absolute error below 0.05 g/cm2.The company's second core product, DeepSono, focuses on automated cardiac ultrasound analysis. Using portable ultrasound devices, DeepSono autonomously outlines myocardial contours and calculates ejection fraction (EF) and global longitudinal strain (GLS)-traditionally requiring manual assessment by cardiologists.AIM's solutions have earned Class II medical device certification from authorities including the US FDA, Taiwan's TFDA, Japan's PMDA, and Vietnam's IMDA, and are expanding to other targeted countries-making it one of the few Taiwanese medical AI startups with comprehensive international certifications.Scalable Business Model and Global ExpansionTo accelerate adoption, AIM offers medical institutions a printer and cartridge business model, including a one-time software license fee at 10% of the full cost to lower entry barriers, followed by a SaaS-based monthly subscription or usage-based billing. Since its 2024 certification, AIM's solutions have been deployed in over 50 clinics and hospitals across Taiwan and Vietnam, with entry into the Japanese market underway."In a competitive global medical AI market, AIM's edge lies in delivering quantitative diagnostic data-not just risk classification," said Lee. While most medical AI solutions on the market only classify patients into high-, medium-, or low-risk categories, AIM goes beyond simply identifying risk levels and provides actionable and clinically relevant number-based metrics. AIM also prioritizes algorithm optimization and platform-based, fully automated diagnostic workflows, significantly enhancing clinical efficiency. Its long-term mission is to democratize precision care by pairing affordable devices with advanced AI technology so that the general public around the world will all be taken care of.Future Roadmap: Elderly Mobility and Cardiac CareLee stated that AIM will continue to expand its product portfolio centered around elderly mobility and cardiac care by leveraging widely available X-ray and ultrasound devices in primary care settings. Upcoming features include sarcopenia risk prediction, enhanced integration of handheld ultrasound with AI, and new developments in abdominal ultrasound, AI-assisted chest disease detection, and preoperative anesthesia risk analysis.Lee also underscored the evolution of Taiwan's startup ecosystem, which in recent years has matured significantly, especially in terms of global outreach. Taiwan Tech Arena (TTA) has actively facilitated overseas market connections and aligned investment resources, supporting AIM in its global expansion. In addition to tapping into international markets, Lee recommends that the government and hospitals provide more PoC/PoB habitats to accelerate the development and global reach of Taiwan's medical AI sector, increase clinical deployment opportunities for startups, and bring precision care to communities around the world.